## Product Overview **Gidazepam Pellets** are described in the supplied information as a laboratory research preparation associated with gidazepam, a synthetic compound belonging to the 1,4-benzodiazepine family. The compound is distinguished by a brominated aromatic structure and a hydrazide-containing substituent. These structural characteristics provide a basis for analytical investigations involving chemical identification, chromatographic differentiation, and spectroscopic characterization. Raw Lab Chems presents this material exclusively within a Research Use Only framework. The supplied source describes compressed pellets intended for controlled laboratory examination. However, the stated presentation does not independently establish the actual chemical identity, purity, finished-unit composition, or content uniformity. The source also refers to independent analytical verification, batch consistency, and controlled manufacturing conditions. These descriptions remain supplier-provided claims until supported by documentation associated with the actual product and batch. No clinical, therapeutic, diagnostic, dietary, or consumer-oriented application is represented by this description. ## Chemical Identity & Classification Gidazepam is a synthetic compound belonging to the **1,4-benzodiazepine** chemical family. The supplied source describes it as a brominated benzodiazepine derivative containing a hydrazide functional group. Its molecular framework provides a basis for comparing gidazepam with other halogenated benzodiazepine-related compounds. The supplied source provides the following chemical-reference information: - **Common name:** Gidazepam - **Chemical classification:** Hydrazide-containing 1,4-benzodiazepine derivative - **Reported molecular formula:** C17H15BrN4O2 - **Related compound:** Desalkylgidazepam - **Reported metabolite description:** 7-Bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepine-2-one No CAS Registry Number or molecular weight was supplied. The reported molecular formula is reproduced from the source and does not independently establish the composition of the actual product. The source does not provide a verified salt-form designation or complete formulation specification. This distinction matters because the composition of a finished pellet may differ from the molecular formula of the named chemical. The source describes gidazepam as a compound associated with metabolic conversion to desalkylgidazepam. That relationship provides scientific context but does not establish the chemical identity or impurity profile of the actual product. Researchers seeking public chemical-reference information may consult [PubChem](https://pubchem.ncbi.nlm.nih.gov/) and confirm that any selected database entry corresponds to the intended compound and chemical form. ## Chemical & Physical Characteristics The supplied product is described as compressed pellets containing gidazepam. No product-specific inspection report, pellet-dimension specification, excipient list, or formulation-characterization record was provided. The stated physical presentation therefore remains a source-provided description. The gidazepam molecular framework contains a 1,4-benzodiazepine ring system and substituents that distinguish it from other benzodiazepine derivatives. These structural features provide a basis for analytical differentiation through chromatographic and spectroscopic techniques. However, structural similarity does not establish identical physical properties, stability, impurity profiles, or analytical behavior. The source identifies the hydrazide-containing structure as relevant to chemical and metabolic research. No product-specific hydrolysis-rate measurements, degradation data, or experimentally verified physicochemical profile accompanied this description. The source also does not provide a verified melting point, quantitative solubility profile, density, particle-size distribution, or hygroscopicity measurement. The finished pellet preparation may contain additional formulation ingredients that were not identified in the source. No verified binder, filler, coating, or excipient information accompanied the supplied material. The source recommends cool, dry storage protected from moisture. No validated stability study, degradation profile, or experimentally established shelf-life specification accompanied this recommendation. ## Purity & Analytical Verification The supplied description claims **purity of at least 98%**, with HPLC cited as a method of verification. It also refers to NMR and mass spectrometry for structural identification and batch consistency. However, no actual batch-specific Certificate of Analysis, chromatogram, NMR spectrum, mass spectrum, or independent laboratory report was provided. Accordingly, the stated purity threshold is not independently confirmed for the material described here. The source identifies LC-MS and GC-MS as analytical techniques associated with gidazepam investigation. Such methods may provide information concerning chemical identity, structural characteristics, impurity profiles, and analytical specificity. However, naming an analytical technique does not establish that it was performed on the actual product. An important distinction exists between the purity of the chemical ingredient and the composition of the finished pellet. Even if ingredient purity were independently established, that finding would not by itself verify the labeled component amount, total formulation, or consistency between individual units. The source also refers to gidazepam-related metabolic research involving desalkylgidazepam. These references provide analytical context rather than evidence of the product's verified performance in a particular laboratory method. No certified reference-material status, validated finished-unit content, or independently established purity specification is asserted. ## Quality Control & Batch Integrity The supplied source claims that individual batches undergo HPLC testing to confirm purity and labeled component content. It also describes NMR and mass-spectrometric verification, batch consistency, and Certificates of Analysis for institutional documentation. No actual certificate, independent testing record, manufacturing audit, laboratory accreditation document, or batch-specific quality-control report accompanied these statements. They therefore remain unverified supplier claims. For reproducible laboratory investigation, useful records may include supplier identification, batch number, chemical identifier, receipt date, storage history, and available analytical findings. For pellet preparations, the identity and purity of the named ingredient should be distinguished from the composition and consistency of the finished units. The supplied information does not establish independently verified content uniformity, excipient composition, or quantitative accuracy of the labeled amount. Where a material is described as suitable for reference-standard work, researchers should distinguish ordinary catalog material from a certified reference material. The supplied information does not establish certified reference-material status, metrological traceability, or an assigned measurement uncertainty. Claims of consistent purity, identity, formulation quality, or manufacturing compliance should be supported by actual analytical records rather than inferred from catalog terminology. ## Safety, Handling & Laboratory Precautions Gidazepam is a benzodiazepine-related compound requiring appropriate institutional risk assessment and controlled laboratory handling. Research personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material. Laboratory precautions should address access restrictions, protective equipment, contamination prevention, accidental exposure, environmental release, and chemical-waste disposal. The compound's structural relationship to other benzodiazepines does not establish safety for human or veterinary exposure. The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments. Because the actual purity and pellet composition have not been independently confirmed, laboratory documentation should distinguish verified characteristics from supplier-provided statements. The pellet presentation must not be interpreted as evidence of pharmaceutical suitability or authorization for personal use. Any accidental exposure or contamination incident should be managed according to institutional emergency procedures. ## Packaging, Labeling & Storage The supplied source describes high-barrier, moisture-resistant packaging intended to protect material integrity during transportation. No packaging-validation study, verified container specification, or actual shipment-condition record accompanied this claim. The source recommends cool, dry storage protected from moisture, with a suggested temperature range of 15–25°C. No validated stability data was provided to establish that this temperature range is necessary or sufficient for a particular shelf life. The source also claims that shipping arrangements support regulatory compliance and safe transit. No shipment classification, carrier documentation, or compliance record was supplied to substantiate those statements. Laboratory inventory records should preserve the compound name, any available batch identifier, receipt details, and relevant storage observations. The labeled pellet content should be recorded as a source-provided specification unless independently confirmed. Where chemical form or formulation ingredients remain uncertain, the inventory record should preserve those uncertainties rather than assign unverified details. Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional laboratory procedures. ## Intended Research Use & Market Positioning The supplied scientific context places gidazepam within analytical research involving 1,4-benzodiazepine derivatives, chemical identification, structural comparison, and forensic toxicology. Its hydrazide-containing molecular framework provides a basis for examining distinctions among related benzodiazepine compounds. The source references chromatographic identification, mass-spectrometric characterization, and investigation of gidazepam-related analytical markers. These references describe laboratory research contexts and do not establish any human-use application. The supplied Raw Lab Chems catalog references include [Gidazepam Pellets](https://rawlabchems.com/product/gidazepam-pellets-3mg/) and a [second Gidazepam Pellets listing](https://rawlabchems.com/product/gidazepam-pellets-3mg-2/). Both links identify similarly named products, but the supplied information does not establish whether they represent separate formulations, duplicate catalog entries, or different inventory records. For related benzodiazepine catalog context, Raw Lab Chems also lists [Bromonordiazepam Pellets](https://rawlabchems.com/product/buy-bromonordiazepam-pellets/). These references identify related research materials but do not establish equivalent chemical identity, purity, formulation, regulatory status, or analytical characteristics. They provide catalog context rather than evidence of certified reference-material status or interchangeability. ## Ordering, Availability & Fulfillment The supplied source describes standardized laboratory quantities, protective packaging, and professional shipping arrangements. However, no current inventory information, carrier record, destination-specific authorization, or verified shipment-performance documentation was provided. Consequently, no specific availability, delivery, customs-clearance, or transportation-compliance guarantee is asserted. Gidazepam may be subject to controlled-substance or other chemical regulations. Institutional acquisition and transfer should therefore be assessed against the applicable laws governing the exact substance and chemical form involved. Researchers and institutions should independently verify whether possession, importation, exportation, transportation, and laboratory investigation are authorized in their jurisdictions. Research-only labeling does not establish an exemption from controlled-substance regulations. ## Legal & Regulatory Disclaimer For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Gidazepam is a benzodiazepine-related compound whose acquisition, possession, transfer, importation, exportation, storage, and laboratory investigation may be restricted or prohibited under applicable controlled-substance or other chemical regulations. The exact legal classification and requirements may vary by jurisdiction. Researchers and institutions remain responsible for determining the applicable legal requirements and obtaining any necessary authorizations. No medical approval, consumer-use authorization, universal legal status, or regulatory exemption is implied by this description.
Gidazepam pellets – 3mg Price range: € 15,00 through € 175,00
Back to products
IPPH Isopropylphenidate phenidate research material from Raw Lab Chems
IPPH (Isopropylhenidate) Price range: € 21,95 through € 529,00

Buy Flunitrazolam Blotters

Price range: € 13,75 through € 180,43

Flunitrazolam Blotters are described as a laboratory research preparation associated with flunitrazolam, a synthetic fluorinated, nitro-substituted triazolobenzodiazepine structurally related to other benzodiazepine derivatives.

Raw Lab Chems identifies this material exclusively within the context of controlled chemical identification, forensic analytical characterization, chromatographic investigation, and research involving benzodiazepine-related compounds.

The supplied information describes a blotter presentation but does not provide a confirmed labeled amount for this specific listing.

Claims concerning ingredient purity, independent testing, standardized blotter content, and specialized storage require supporting Raw Lab Chems batch-specific documentation.

The material is not established as a certified reference standard or a validated quantitative calibrator.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-P-13188 Category:
Description

Flunitrazolam Blotters – Triazolobenzodiazepine Research Material

Product Overview

Flunitrazolam Blotters are described in the supplied information as a laboratory research preparation associated with flunitrazolam, a synthetic compound belonging to the triazolobenzodiazepine family.

The compound is structurally related to other substituted benzodiazepine derivatives and is distinguished by its fluorinated aromatic substituent and nitro-containing molecular framework.

These structural characteristics provide a basis for analytical investigations involving chemical identification, chromatographic differentiation, and spectroscopic characterization.

Raw Lab Chems presents this material exclusively within a Research Use Only framework.

The supplied source describes a blotter presentation intended for controlled laboratory examination.

However, the stated presentation does not independently establish the actual chemical identity, purity, finished-unit composition, or content uniformity.

The source also refers to independent analytical verification, controlled storage, and standardized preparation.

These statements originated in material associated with another supplier and cannot be attributed to Raw Lab Chems without independent documentation.

No clinical, therapeutic, diagnostic, dietary, or consumer-oriented application is represented by this description.

Chemical Identity & Classification

Flunitrazolam is a synthetic compound belonging to the triazolobenzodiazepine family.

The supplied source describes it as a fluorinated, nitro-substituted derivative structurally related to other benzodiazepine compounds.

Its fused triazole-benzodiazepine framework provides a basis for differentiating it from structurally related substances.

The supplied source provides the following chemical-reference information:

  • Common name: Flunitrazolam
  • Reported systematic name: 6-(2-Fluorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
  • Chemical classification: Fluorinated, nitro-substituted triazolobenzodiazepine
  • Reported CAS Registry Number: 2243815-18-9
  • Reported molecular formula: C17H12FN5O2
  • Reported molecular weight: 337.31 g/mol

These identifiers are reproduced from the supplied information and do not independently verify the composition of the actual product.

The reported molecular formula and molecular weight are arithmetically consistent with one another.

However, consistency between a formula and calculated mass does not establish that the actual blotter ingredient has been independently identified.

The source does not provide a verified salt-form designation or complete formulation specification.

This distinction matters because the composition of a finished blotter may differ from the molecular formula of the named chemical.

Researchers seeking public chemical-reference information may consult PubChem and confirm that any selected database entry corresponds to the intended compound and chemical form.

Chemical & Physical Characteristics

The supplied product is described as blotters containing flunitrazolam.

No product-specific inspection report, blotter-substrate specification, excipient list, or formulation-characterization record was provided.

The stated physical presentation therefore remains a source-provided description.

The flunitrazolam molecular framework contains a fused triazole-benzodiazepine ring system and substituents that distinguish it from other benzodiazepine compounds.

These structural features provide a basis for analytical differentiation through chromatographic and spectroscopic techniques.

However, structural similarity does not establish identical physical properties, stability, impurity profiles, or analytical behavior.

The source describes the unformulated compound as a white to off-white powder.

No actual batch-specific inspection record or physical characterization dataset was supplied to confirm that appearance.

The finished blotter preparation may also contain substrate materials and additional formulation ingredients.

No verified blotter dimensions, substrate composition, component distribution, or content-uniformity measurements accompanied the supplied information.

The source recommends dry, dark storage under controlled temperature conditions.

No validated stability study, degradation profile, or experimentally established shelf-life specification accompanied this recommendation.

Researchers should distinguish general storage guidance from verified stability data associated with a particular batch.

Purity & Analytical Verification

The supplied description claims ingredient purity of at least 98% and refers to independent quality-control testing.

However, no actual Raw Lab Chems batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, or independent laboratory report was provided.

Accordingly, the stated purity threshold is not independently confirmed for the material described here.

The source identifies LC-MS/MS, UPLC-MS/MS, GC-MS, and NMR spectroscopy as analytical techniques associated with flunitrazolam investigation.

Such methods may provide information concerning chemical identity, structural characteristics, impurity profiles, and analytical specificity.

However, naming an analytical technique does not establish that it was performed on the actual product.

An important distinction exists between the purity of the chemical ingredient and the composition of the finished blotter.

Even if ingredient purity were independently established, that finding would not by itself verify the labeled component amount, total formulation, or consistency between individual units.

The source also refers to forensic toxicology investigations involving flunitrazolam and related analytical markers.

These references provide scientific context rather than evidence of the product’s verified performance in a particular laboratory method.

No certified reference-material status, validated finished-unit content, or independently established purity specification is asserted.

Quality Control & Batch Integrity

The supplied source claims that individual batches undergo independent testing and are supported by Certificates of Analysis.

It also describes analytical purity profiles, standardized blotter content, controlled storage, and specialized packaging.

No actual certificate, independent testing record, manufacturing audit, laboratory accreditation document, or batch-specific quality-control report accompanied these statements.

They therefore remain unverified claims.

Furthermore, the source refers to a supplier other than Raw Lab Chems.

Its quality-control representations should not be transferred to a Raw Lab Chems product listing without supporting documentation from the relevant supplier.

For reproducible laboratory investigation, useful records may include supplier identification, batch number, chemical identifier, receipt date, storage history, and available analytical findings.

For blotter preparations, the identity and purity of the named ingredient should be distinguished from the composition and consistency of the finished units.

The supplied information does not establish independently verified content uniformity, substrate composition, or quantitative accuracy of any labeled amount.

Where a material is described as suitable for reference-standard work, researchers should distinguish ordinary catalog material from a certified reference material.

The supplied information does not establish certified reference-material status, metrological traceability, or an assigned measurement uncertainty.

Safety, Handling & Laboratory Precautions

Flunitrazolam is a benzodiazepine-related compound requiring appropriate institutional risk assessment and controlled laboratory handling.

The source associates the compound with serious central nervous system depressant hazards, including profound impairment and potentially life-threatening toxicity following exposure.

Research personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.  Flunitrazolam Blotters

Laboratory precautions should address access restrictions, protective equipment, contamination prevention, accidental exposure, environmental release, and chemical-waste disposal.

The compound’s structural relationship to other benzodiazepines does not establish safety for human or veterinary exposure.

The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.

Because the actual purity and blotter composition have not been independently confirmed, laboratory documentation should distinguish verified characteristics from supplier-provided statements.

The blotter presentation must not be interpreted as evidence of pharmaceutical suitability or authorization for personal use.

Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.

Packaging, Labeling & Storage

The supplied source describes double-sealed packaging, temperature-controlled logistics, and tracking during transportation.

No Raw Lab Chems packaging-validation study, verified container specification, shipment-condition record, or carrier documentation accompanied these claims.

The source recommends storage in a dry, dark environment under controlled temperature conditions.  Flunitrazolam Blotters

No validated stability data was provided to establish a specific temperature range or product-specific shelf life.

Claims concerning cold-chain storage and transport therefore remain unverified.

Laboratory inventory records should preserve the compound name, any available batch identifier, receipt details, and relevant storage observations.

Any labeled blotter content should be recorded as a source-provided specification unless independently confirmed.

Where chemical form or formulation ingredients remain uncertain, the inventory record should preserve those uncertainties rather than assign unverified details.

Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional laboratory procedures.

Intended Research Use & Market Positioning

The supplied scientific context places flunitrazolam within analytical research involving triazolobenzodiazepine derivatives, chemical identification, structural comparison, and forensic toxicology.  Flunitrazolam Blotters

Its substituted molecular framework provides a basis for differentiating it from other benzodiazepine-related compounds in appropriately validated analytical investigations.

The source references chromatographic identification, mass-spectrometric characterization, and investigation of benzodiazepine-related analytical markers.

These references describe laboratory research contexts and do not establish any human-use application.

For comparative chemical-catalog context, Raw Lab Chems also lists Gidazepam Pellets and a second Gidazepam Pellets catalog entry.    Flunitrazolam Blotters

These listings identify other named products but do not establish equivalent chemical identity, composition, purity, regulatory status, or analytical characteristics.

The supplied Flunitrazolam Blotters catalog reference identifies the product page associated with the material discussed here.

These references provide catalog context rather than evidence of certified reference-material status or interchangeability.

Ordering, Availability & Fulfillment

The supplied source includes claims concerning available pack sizes, European shipping coverage, same-day dispatch, delivery time frames, carrier services, and payment options.

However, those statements reference another supplier and are not verified Raw Lab Chems fulfillment specifications.

No current Raw Lab Chems inventory record, shipping schedule, destination-specific authorization, or carrier documentation was supplied.

Consequently, no particular availability, delivery period, shipping cost, customs-clearance arrangement, or transportation-compliance guarantee is asserted.

Flunitrazolam may be subject to strict controlled-substance legislation.

Institutional acquisition and transfer should therefore be assessed against the applicable laws governing the exact substance and chemical form involved.  Flunitrazolam Blotters

Researchers and institutions should independently verify whether possession, importation, exportation, transportation, and laboratory investigation are authorized in their jurisdictions.

Research-only labeling does not establish an exemption from controlled-substance regulations.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Flunitrazolam is a triazolobenzodiazepine whose acquisition, possession, transfer, importation, exportation, storage, and laboratory investigation may be restricted or prohibited under applicable controlled-substance or other chemical regulations.  Flunitrazolam Blotters

The supplied source identifies regulatory restrictions in several jurisdictions, but the exact current legal classification was not independently verified for this listing.

Researchers and institutions remain responsible for determining the applicable legal requirements and obtaining any necessary authorizations.

No medical approval, consumer-use authorization, universal legal status, or regulatory exemption is implied by this description.

Additional information
Quantity

25 blotters

,

50 blotters

,

100 blotters

,

250 blotters

,

500 blotters

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Buy Flunitrazolam Blotters”
Shipping & Delivery